![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, September 27, 2019 1:21:23 PM
Ah...... it was approved 2 months ago in the EU.
This was the FDA.
Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis
https://finance.yahoo.com/news/enanta-hcv-collaboration-partner-abbvie-125100455.html
****************************
An aside; This continues to only improve as the easiest, fastest HCV treatment.
There are still huge numbers to treat, and the ability to prescribe and start treating w/o genotyping, doing viral load tests, without needing higher competency in treating physicians seems like the market share may continue to grow.
I WONDER? Seeing how successful this treatment has become, seeing a long treatment tail, I wonder what would have happened if somehow ENTA had been able to have paid for half the trials? What kind of money would they have spent, versus what they might currently be making, now, and in the future?
Recent ENTA News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 12:38:39 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:15:05 PM
- Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:37:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:00:34 PM
- Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference • Business Wire • 05/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:05:14 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 05/06/2024 08:01:00 PM
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 11:10:00 AM
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer • Business Wire • 04/30/2024 11:00:00 AM
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 • Business Wire • 04/29/2024 11:00:00 AM
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
- Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference • Business Wire • 03/06/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:31:52 PM
- Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/27/2024 06:11:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:23:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:21:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:18:12 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM